Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma on the basis of recurrence-free and overall survival rates that were higher than those with placebo in a phase 3 trial. We wanted to determine the efficacy of nivolumab versus ipilimumab for adjuvant therapy in patients with resected advanced melanoma. METHODS: In this randomized, double-blind, phase 3 trial, we randomly assigned 906 patients (≥15 years of age) who were undergoing complete resection of stage IIIB, IIIC, or IV melanoma to receive an intravenous infusion of either nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks (453 patients) or ipilimumab at a dose of 10 mg per kilogram every 3 weeks for four doses and then every 12 weeks (453 patients). The patients were treated for a period of up to 1 year or until disease recurrence, a report of unacceptable toxic effects, or withdrawal of consent. The primary end point was recurrence-free survival in the intention-to-treat population. RESULTS: At a minimum follow-up of 18 months, the 12-month rate of recurrence-free survival was 70.5% (95% confidence interval [CI], 66.1 to 74.5) in the nivolumab group and 60.8% (95% CI, 56.0 to 65.2) in the ipilimumab group (hazard ratio for disease recurrence or death, 0.65; 97.56% CI, 0.51 to 0.83; P<0.001). Treatment-related grade 3 or 4 adverse events were reported in 14.4% of the patients in the nivolumab group and in 45.9% of those in the ipilimumab group; treatment was discontinued because of any adverse event in 9.7% and 42.6% of the patients, respectively. Two deaths (0.4%) related to toxic effects were reported in the ipilimumab group more than 100 days after treatment. CONCLUSIONS: Among patients undergoing resection of stage IIIB, IIIC, or IV melanoma, adjuvant therapy with nivolumab resulted in significantly longer recurrence-free survival and a lower rate of grade 3 or 4 adverse events than adjuvant therapy with ipilimumab. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 238 ClinicalTrials.gov number, NCT02388906 ; Eudra-CT number, 2014-002351-26 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nonetheless, adjuvant ICT has been successful in high-risk melanoma, which led to FDA approval (189-193).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [191]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationFinal Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationWeber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Self-citationCompletion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., Jahkola, T., Bowles, T. L., Testori, A., Beitsch, P. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613210 · Cited by 1,414
Research works printed but not linked: 1
- Tarhini AA, 2017, J Clin Oncol, 35
Cited by
Items 401–500 of 1,000
Blankenstein, S. A., Rohaan, M. W., Klop, W. M. C., van der Hiel, B., van de Wiel, B. A., Lahaye, M. J., Adriaansz, S., Sikorska, K., van Tinteren, H., Sari, A., et al. (2021) · Annals of Surgery · doi:10.1097/sla.0000000000004893 · Cited by 49
“Nowadays, these patients are also eligible for adjuvant systemic therapy with nivolumab.(17) Neoadjuvant treatment in these patients may also reduce the development of new metastatic lesions from undetected micrometastatic disease.”
BackgroundBateni, S. B., Nguyen, P., Eskander, A. E., Seung, S. J., Mittmann, N., Jalink, M., Gupta, A., Chan, K., Hong, N. J. L., & Hanna, T. P. (2023) · JAMA Dermatology · doi:10.1001/jamadermatol.2023.3179 · Cited by 49
“9) visits or a median (IQR) of 10 (5-18) visits for injection and/or oral systemic therapy.”
BackgroundRobert, C., Gastman, B., Gogas, H. J., Rutkowski, P., Long, G. V., Chaney, M. F., Joshi, H., Lin, Y., SNYDER, W. J., & Chesney, J. A. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114120 · Cited by 53
Self-citationUnravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
Wu, L., Tsang, V., Sasson, S. C., Menzies, A. M., Carlino, M. S., Brown, D. A., Clifton-Bligh, R. J., & Gunton, J. E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.764138 · Cited by 48
“In addition to metastatic malignancies, adjuvant ICI therapy with anti-PD1 has also been demonstrated to reduce risk of relapse in resected stage III or IV melanoma and resected renal cell carcinoma (11, 12).”
Backgroundvan Akkooi, A. C. J., Hieken, T. J., Burton, E. M., Ariyan, C. E., Ascierto, P. A., Asero, S. V. M. A., Blank, C. U., Block, M. S., Boland, G. M., Caracò, C., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-021-11236-y · Cited by 50
Self-citationVreeland, T. J., Clifton, G. T., Hale, D. F., Chick, R. C., Hickerson, A. T., Cindass, J. L., Adams, A. M., Bohan, P. M. K., Andtbacka, R. H. I., Berger, A. C., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-09709-1 · Cited by 46
Yuen, K. C. J., Samson, S. L., Bancos, I., Gosmanov, A. R., Jasim, S., Fecher, L. A., & Weber, J. S. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.04.010 · Cited by 46
Self-citationMetastatic Melanoma: Recent Therapeutic Progress and Future Perspectives
Malissen, N., & Grob, J. (2018) · Drugs · doi:10.1007/s40265-018-0945-z · Cited by 51
Self-citationAlbertini, M. R., Yang, R. K., Ranheim, E. A., Hank, J. A., Zuleger, C., Weber, S. M., Neuman, H. B., Hartig, G., Weigel, T. L., Mahvi, D., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2223-z · Cited by 45
“8%) for patients with resected stage IIIB, IIIC, or IV melanoma [25].”
Onesti, C. E., Frères, P., & Jérusalem, G. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.12.47 · Cited by 46
“In melanoma several phase III clinical trials evaluated ipilimumab, nivolumab and pembrolizumab in completely resected high risk patients, showing a relapse free survival (RFS) benefit (12,13).”
BackgroundLiver damage related to immune checkpoint inhibitors
Nishida, N., & Kudo, M. (2019) · Hepatology International · doi:10.1007/s12072-018-9921-7 · Cited by 46
Verver, D., van der Veldt, A., van Akkooi, A. C. J., Verhoef, C. K., Grünhagen, D. J., & Louwman, W. (2019) · International Journal of Cancer · doi:10.1002/ijc.32229 · Cited by 45
Wang, X., Kong, Y., Chi, Z., Sheng, X., Cui, C., Mao, L., Lian, B., Tang, B., Yan, X., Si, L., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13034 · Cited by 45
Mekki, A., Dercle, L., Lichtenstein, P., Nasser, G., Marabelle, A., Champiat, S., Chouzenoux, É., Balleyguier, C., & Ammari, S. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.06.020 · Cited by 46
“In contrast, HP is less frequent in patients treated with anti-PD-1 or anti-PD-L1 monotherapy [25].”
BackgroundHaydu, L. E., Lo, S., McQuade, J. L., Amaria, R. N., Wargo, J. A., Ross, M. I., Cormier, J. N., Lucci, A., Lee, J. E., Ferguson, S. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01508 · Cited by 45
“Age, years Median (range) 56 (16-95) 57 (17-95) 55 (16-89) .”
Self-citationPrognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma
Hoffmann, F., Zarbl, R., Niebel, D., Sirokay, J. D., Fröhlich, A., Posch, C., Holderried, T. A. W., Brossart, P., Saavedra, G., Kuster, P., et al. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00883-9 · Cited by 46
“Background Immune checkpoint inhibitors of the programmed cell death (PD-1) pathway are able to induce dramatic and durable regression of metastatic melanoma, consequently leading to their regulatory approval in metastatic melanoma and also recently in the adjuvant setting [1, 2].”
BackgroundCombining common genetic variants and non-genetic risk factors to predict risk of cutaneous melanoma
Gu, F., Chen, T.-H., Pfeiffer, R. M., Fargnoli, M. C., Calista, D., Ghiorzo, P., Peris, K., Puig, S., Menin, C., Nicolo, A. D., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy282 · Cited by 49
Huang, Q., Zheng, Y., Gao, Z., Yuan, L., Sun, Y., & Chen, H. (2020) · Journal of Cancer · doi:10.7150/jca.49325 · Cited by 48
Novel adjuvant options for cutaneous melanoma
Dimitriou, F., Long, G. V., & Menzies, A. M. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.198 · Cited by 52
Self-citationMoncrieff, M. D., Lo, S., Scolyer, R. A., Heaton, M. J., Nobes, J. P., Snelling, A. P., Carr, M. J., Nessim, C., Wade, R. G., Peach, A. H. S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02488 · Cited by 48
“Recently, several prospective randomized controlled trials have shown clinical benefit of adjuvant systemic therapy, in terms of recurrence-free survival, for patients with AJCC stage III metastatic melanoma.(2,4,5) As a result, most modern clinical guidelines recommend it for high-risk, resected stage III disease.”
BackgroundPD-L1: Biological mechanism, function, and immunotherapy in gastric cancer
Zhang, Y., Yang, Y., Chen, Y., Wu, L., Chen, X., Liu, J., Huang, Y., Wang, H., & Teng, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1060497 · Cited by 45
“Agents against PD-L1/PD-1 have shown significant clinical significance in non-small-cell-lung-cancer (NSCLC) (11), melanoma (12) and GC (5) amongst others.”
BackgroundShin, Y. E., Kumar, A., & Guo, J. J. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01254-x · Cited by 43
“Ipilimumab is primarily used in combination with nivolumab because of its inferiority as monotherapy to pembrolizumab [27] and nivolumab [28] and evidence that the combination improves overall survival and response to therapy [29–31].”
BackgroundSeidl, S., Schuster, B., Rüth, M., Biedermann, T., & Zink, A. (2018) · Journal of Medical Internet Research · doi:10.2196/10327 · Cited by 47
Expert opinion on thyroid complications in immunotherapy
Illouz, F., Drui, D., Caron, P. J., & Cao, C. D. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.07.007 · Cited by 47
Riefolo, M., Porcellini, E., Dika, E., Broseghini, E., & Ferracin, M. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12412 · Cited by 47
“Recently, immunotherapy with checkpoint inhibitors targeting cytotoxic T lymphocyte-associated antigen 4, CTLA-4 (ipilimumab) and programmed death 1, PD-1 (pembrolizumab and nivolumab) have also been demonstrated to provide durable effects in metastatic melanoma, which improved when combined together (Larkin et al., 2…”
BackgroundPrognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy
Rizk, E. M., Gartrell, R. D., Barker, L. W., Esancy, C. L., Finkel, G. G., Bordbar, D. D., & Saenger, Y. M. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.12.005 · Cited by 47
Radiotherapy for Melanoma: More than DNA Damage
Rogers, S. J., Puric, E., Eberle, B., Datta, N. R., & Bodis, S. B. (2019) · Dermatology Research and Practice · doi:10.1155/2019/9435389 · Cited by 51
Neoadjuvant immunotherapy for melanoma
Lee, A. Y., & Brady, M. S. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.26229 · Cited by 43
Ziogas, D. C., Gkoufa, A., Cholongitas, E., Diamantopoulos, P., Anastasopoulou, A., Ascierto, P. A., & Gogas, H. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001322 · Cited by 43
Self-citationLian, B., Si, L., H., Z., Sheng, X., Kong, Y., Wang, X., Tian, H., Li, K., Mao, L., Bai, X. L., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.002 · Cited by 43
Tolstrup, L. K., Bastholt, L., Dieperink, K. B., Möller, S., Zwisler, A., & Pappot, H. (2020) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-020-00255-0 · Cited by 44
It is finally time for adjuvant therapy in melanoma
Napolitano, S., Brancaccio, G., Argenziano, G., Martinelli, E., Morgillo, F., Ciardiello, F., & Troiani, T. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.06.003 · Cited by 45
Zhao, B., Zhao, H., & Zhao, J. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0421-z · Cited by 46
“Weber, 2017 [13] 3 Melanoma 453 56(19–83) 258/195 Nivolumab 3 mg/kg every 14 days 12.”
Updates in adjuvant systemic therapy for melanoma
Kwak, M., Farrow, N. E., Salama, A. K. S., Mosca, P. J., Hanks, B. A., Slingluff, C. L., & Beasley, G. M. (2018) · Journal of Surgical Oncology · doi:10.1002/jso.25298 · Cited by 46
“BRIM8 was the only adjuvant trial to include patients with stage IIC disease.(3,4,8) Importantly, the expected 5‐ and 10‐year melanoma‐specific survival of patients with AJCC v8 stage”
BackgroundInfluentialRole of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
Sahni, S., Valecha, G. K., & Sahni, A. (2018) · Cureus · doi:10.7759/cureus.3700 · Cited by 49
Sun, L., Chin, R.-I., Gastman, B., Thorstad, W. L., Yom, S. S., Reddy, C. A., Nussenbaum, B. A., Wang, S. J., Knackstedt, T., Vidimos, A. T., et al. (2019) · JAMA Dermatology · doi:10.1001/jamadermatol.2018.5453 · Cited by 42
Nahar, K. J., Rawson, R. V., Ahmed, T., Tattersall, S., Sandanayake, N. S., Kiely, C. J., Lo, S., Carlino, M. S., Palendira, U., Scolyer, R. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001488 · Cited by 43
Self-citationYu, Z., Wang, H., Chen, Z., Dong, X., Zhao, W., Shi, Y., & Zhu, Q. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02154 · Cited by 44
Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults
Schonfeld, S. J., Tucker, M. A., Engels, E. A., Dores, G. M., Sampson, J. N., Shiels, M. S., Chanock, S. J., & Morton, L. M. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.3461 · Cited by 44
Cutaneous melanoma in adolescents and young adults
Indini, A., Brecht, I. B., Vecchio, M. D., Sultan, I. Y., Signoroni, S., & Ferrari, A. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27292 · Cited by 44
Identification of risk in cutaneous melanoma patients: Prognostic and predictive markers
Hyams, D. M., Cook, R. W., & Buzaid, A. C. (2018) · Journal of Surgical Oncology · doi:10.1002/jso.25319 · Cited by 45
“The recent development of effective systemic drug therapy for melanoma has significantly changed patient management and outcomes, particularly in more advanced disease.(4,5) Several studies of stage IV disease demonstrate greater efficacy of immune checkpoint inhibitors (ICIs) and MAP‐kinase directed drugs in patients…”
BackgroundOliva, I. C. G., & Alqusairi, R. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02505-2_2 · Cited by 41
Freeman, M. L., & Laks, S. (2019) · Melanoma Management · doi:10.2217/mmt-2019-0003 · Cited by 41
Current and emerging systemic therapies for cutaneous metastatic melanoma
Mason, R., Au, L., Garces, A. I., & Larkin, J. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1601700 · Cited by 46
Self-citationJohannet, P. M., Liu, W., Fenyö, D., Wind‐Rotolo, M., Krogsgaard, M., Mehnert, J. M., Weber, J. S., Zhong, J., & Osman, I. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0404 · Cited by 43
“Adjuvant immune checkpoint blockade (ICB) produces clinical benefit for patients with resectedmelanoma, butmany suffer recurrent disease (1, 2).”
BackgroundMethodResultSelf-citationImmunomodulatory effect of locoregional therapy in the tumor microenvironment
Xie, L., & Meng, Z. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.017 · Cited by 42
Curkovic, N. B., Bai, K., Ye, F., & Johnson, D. B. (2024) · Cancers · doi:10.3390/cancers16020340 · Cited by 50
Gold nanostructures in melanoma: Advances in treatment, diagnosis, and theranostic applications
Dastgheib, Z. S., Abolmaali, S. S., Farahavar, G., Salmanpour, M., & Tamaddon, A. M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35655 · Cited by 46
“These versatile nanoparticles represent a promising frontier in modern medicine, offering multifaceted solutions for improved patient care and outcomes [24,25].”
BackgroundGong, J., Hendifar, A. E., Tuli, R., Chuang, J., Cho, M. T., Chung, V. M., Li, D., & Salgia, R. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0210-9 · Cited by 42
Nijhuis, A. A. G., Dieng, M., Khanna, N., Lord, S. J., Dalton, J., Menzies, A. M., Turner, R. M., Allen, J., Saw, R. P. M., Nieweg, O. E., et al. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07311-0 · Cited by 40
Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives
Testori, A., Ribero, S., Indini, A., & Mandalà, M. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00456-4 · Cited by 45
New paradigm for stage III melanoma: from surgery to adjuvant treatment
Ascierto, P. A., Borgognoni, L., Botti, G., Guida, M., Marchetti, P., D, S. M. M., Muto, P., Palmieri, G., Patuzzo, R., Quaglino, P., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2012-2 · Cited by 42
Self-citationHuman Plasmacytoid Dendritic Cells and Cutaneous Melanoma
Monti, M., Consoli, F., Vescovi, R., Bugatti, M., & Vermi, W. (2020) · Cells · doi:10.3390/cells9020417 · Cited by 43
Novel treatment strategies for early-stage lung cancer: the oncologist’s perspective
Indini, A., Rijavec, E., Bareggi, C., & Grossi, F. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.02.46 · Cited by 44
“Evidence from cutaneous melanoma suggest that ICIs might be effective in the setting of minimal residual disease, in which the tumor microenvironment is immature and therefore easier to overcome, compared to metastatic disease (34).”
BackgroundReview of diagnostic, prognostic, and predictive biomarkers in melanoma
Ankeny, J. S., Labadie, B. W., Luke, J. J., Hsueh, E. C., Messina, J. L., & Zager, J. S. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9892-z · Cited by 39
Tarhini, A. A., Ghate, S. R., Ionescu‐Ittu, R., Manceur, A. M., Ndife, B. C., Jacques, P., Laliberté, F., Nakasato, A. R., Burne, R. M., & Duh, M. S. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000507 · Cited by 39
González, A. (2018) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0379-0 · Cited by 39
Faury, S., & Foucaud, J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227344 · Cited by 44
“HRQOL was a secondary endpoint in nine trials [49,50,51,52,53,54,55,56,57], an exploratory endpoint in five RCTs [58,59,60,61,62] and for one trial it was unclear if the HRQOL endpoints were secondary or Health-related quality of life assessment, cancer and immune checkpoint inhibitors: A systematic review”
BackgroundAdjuvant Therapy for Melanoma: Past, Current, and Future Developments
Testori, A., Chiellino, S., & van Akkooi, A. C. J. (2020) · Cancers · doi:10.3390/cancers12071994 · Cited by 40
“9%, making this a more attractive adjuvant therapy, in terms of both AEs and efficacy [46].”
BackgroundPast, Present, and Future of Anticancer Nanomedicine
Kim, K., & Khang, D. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s254774 · Cited by 46
Ultraviolet radiation drives mutations in a subset of mucosal melanomas
Mundra, P. A., Dhomen, N. S., Rodrigues, M. J., Mikkelsen, L. H., Cassoux, N., Brooks, K. M., Valpione, S., Reis-Filho, J. S., Heegaard, S., Stern, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20432-5 · Cited by 43
Han, J. W., & Yoon, S. K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091387 · Cited by 42
“The use of adjuvant pembrolizumab in stage III resected patients [37] and nivolumab in stage III and IV resected patients [38] reduced the risk of relapse by 40–50% and was approved by the FDA.”
BackgroundAmaral, T. M. S., Sinnberg, T. W., Chatziioannou, E., Niessner, H., Leiter, U., Keim, U., Forschner, A., Dwarkasing, J. T., Tjien-Fooh, F. J., Wever, R., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.12.021 · Cited by 41
Grob, J., Schadendorf, D., Lorigan, P. C., Ascierto, P. A., Larkin, J., Nathan, P., Robert, C., Hauschild, A., Weber, J. S., DAUD, A. I., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.11.023 · Cited by 39
“In melanoma, we are now in a crucial period in the management of stage III disease with the introduction of new and effective targeted and immune strategies in the adjuvant setting [2,3].”
BackgroundSelf-citationDailah, H. G., Hommdi, A. A., Koriri, M. D., Algathlan, E. M., & Mohan, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24559 · Cited by 48
Tanaka, N., Kanatani, S., Kaczyńska, D., Fukumoto, K., Louhivuori, L. M., Mizutani, T., Kopper, O., Kronqvist, P., Robertson, S., Lindh, C., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0576-z · Cited by 40
Tonella, L., Pala, V., Ponti, R., Rubatto, M., Gallo, G., Mastorino, L., Avallone, G., Merli, M., Agostini, A., Fava, P., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094561 · Cited by 41
“Despite the good results obtained in terms of PFS and OS [11,14,15], there is a high need for reproducible, sensitive, and “easy-to-use” biomarkers, to guide the clinical decision-making process.”
BackgroundFertility preservation and management of pregnancy in melanoma patients requiring systemic therapy
Hassel, J. C., Livingstone, E., Allam, J., Behre, H. M., Bojunga, J., Klein, H. H., Landsberg, J., Nawroth, F., Schüring, A. N., Susok, L., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100248 · Cited by 45
Tetzlaff, M. T., Adhikari, C., Lo, S., Rawson, R. V., Amaria, R. N., Menzies, A. M., Wilmott, J. S., Ferguson, P. M., Ross, M. I., Spillane, A. J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.016 · Cited by 37
Self-citationImmunotherapy-induced Hepatotoxicity: A Review
Cunha, T. D., Wu, G. Y., & Vaziri, H. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00105 · Cited by 49
Deep learning detection of melanoma metastases in lymph nodes
Jansen, P., Baguer, D. O., Duschner, N., Arrastia, J. L., Schmidt, M., Landsberg, J., Wenzel, J., Schadendorf, D., Hadaschik, E. N., Maaß, P., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.04.023 · Cited by 41
Management of acral lentiginous melanoma: current updates and future directions
Dugan, M. M., Perez, M. C., Karapetyan, L., & Zager, J. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1323933 · Cited by 39
“The CheckMate 238 phase III trial compared adjuvant therapy with either nivolumab or ipilimumab for patients with resected stage IIIB-C or IV cutaneous melanoma, and found a signi fi cantly improved RFS with nivolumab (38).”
MethodLiquid biopsy: paving a new avenue for cancer research
Kurma, K., Eslami‐S, Z., Alix‐Panabières, C., & Cayrefourcq, L. (2024) · Cell Adhesion & Migration · doi:10.1080/19336918.2024.2395807 · Cited by 43
“…latest breakthrough in the field and stands as a significant advancement in the ongoing fight against diverse cancers such as metastatic melanoma [202], kidney cancer [203], bladder cancer [204], NSCLC [205,206], small cell lung cancer [207], gastric cancer [208], breast cancer [209], liver…”
BackgroundPrinciples of Immunotherapy in Melanoma
Onitilo, A. A., & Wittig, J. A. (2019) · Surgical Clinics of North America · doi:10.1016/j.suc.2019.09.009 · Cited by 42
Smith, H. G., Glen, J., Turnbull, N., Peach, H., Ruth Board, Payne, M., Gore, M. E., Nugent, K. P., & Smith, M. J. F. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.04.041 · Cited by 38
Management of Immune Checkpoint Inhibitor Toxicities
Durrechou, Q., Domblides, C., Sionneau, B., Lefort, F., Quivy, A., Ravaud, A., Gross‐Goupil, M., & Daste, A. (2020) · Cancer Management and Research · doi:10.2147/cmar.s218756 · Cited by 39
Zhou, J., Liang, B., Liu, J., Jin, S., He, S., Frey, B., Gu, N., Fietkau, R., Hecht, M., Ma, H., et al. (2021) · Cells · doi:10.3390/cells10050977 · Cited by 50
“Therapies based on blockade of PD-1 in human melanoma achieved a success [6,7]; nivolumab (an anti-PD-1 monoclonal antibody) [8], and pembrolizumab (another anti-PD-1 monoclonal antibody) [9] monotherapy improve relapse/recurrence-free survival of stage III melanoma patients.”
BackgroundGenetic analysis of cancer drivers reveals cohesin and CTCF as suppressors of PD-L1
Oreskovic, E., Wheeler, E. C., Mengwasser, K. E., Fujimura, E., Martin, T. D., Tóthová, Z., & Elledge, S. J. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2120540119 · Cited by 40
Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients
Tong, J., Kartolo, A., Yeung, C., Hopman, W. M., & Baetz, T. D. (2022) · Current Oncology · doi:10.3390/curroncol29100629 · Cited by 43
Rohaan, M. W., Stahlie, E. H. A., Franke, V., Zijlker, L. P., Wilgenhof, S., van der Noort, V., van Akkooi, A. C. J., & Haanen, J. B. A. G. (2022) · BMC Cancer · doi:10.1186/s12885-022-09896-4 · Cited by 40
Immune checkpoint inhibitors in metastatic melanoma therapy (Review)
Shah, V., Panchal, V. S., Shah, A., Vyas, B., Agrawal, S. P., & Bharadwaj, S. P. (2024) · Medicine International · doi:10.3892/mi.2024.137 · Cited by 41
“In patients with stage III or stage IV melanoma, adjuvant therapy was administered with either nivolumab (n=453) or ipilimumab (n=453) and follow‑up was performed after 18 months (82).”
BackgroundVerver, D., Klaveren, D. V., Franke, V., van Akkooi, A. C. J., Rutkowski, P. L., Keilholz, U., Eggermont, A. M. M., Nijsten, T. E. C., Grünhagen, D. J., & Verhoef, C. K. (2018) · British journal of surgery · doi:10.1002/bjs.10995 · Cited by 39
Self-citationPD-1 Blockade in Early-Stage Lung Cancer
Rosner, S., Reuss, J. E., & Forde, P. M. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-050217-025205 · Cited by 39
Is earlier better for melanoma checkpoint blockade?
Robert, C. (2018) · Nature Medicine · doi:10.1038/s41591-018-0250-0 · Cited by 39
The Emerging Use of Immune Checkpoint Blockade in the Adjuvant Setting for Solid Tumors: A Review
Moujaess, E., Haddad, F., Eid, R., & Kourié, H. R. (2019) · Immunotherapy · doi:10.2217/imt-2019-0087 · Cited by 41
Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect
Bai, X. L., & Flaherty, K. T. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19394 · Cited by 42
Efficacy of immune checkpoint inhibitors in different types of melanoma
Rossi, E., Schinzari, G., Maiorano, B. A., Indellicati, G., Stefani, A. D., Pagliara, M. M., Fragomeni, S. M., Luca, E. V. D., Sammarco, M. G., Garganese, G., et al. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1771986 · Cited by 42
“%) enrolled in the ChechMate 238 trial had MM.51 The limited studies available demonstrated that patients with MM may benefit from anti–PD-1 therapy, although the probability of benefits is lower than in cutaneous melanoma.”
BackgroundInfluentialBoekhout, A. H., Rogiers, A., Jóźwiak, K., Boers‐Sonderen, M. J., van den Eertwegh, A. J. M., Hospers, G. A. P., de Groot, J. W. B., Aarts, M. J. B., Kapiteijn, E., ten Tije, A. J., et al. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1818823 · Cited by 37
Yu, Y., Zheng, P., Gao, L., Li, H., Tao, P., Dengfeng, W., Ding, F., Shi, Q., & Chen, H. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000346 · Cited by 41
Guidelines for clinical evaluation of anti‐cancer drugs
Minami, H., Kiyota, N., Kimbara, S., Ando, Y., Shimokata, T., Ohtsu, A., Fuse, N., Kuboki, Y., Shimizu, T., Yamamoto, N., et al. (2021) · Cancer Science · doi:10.1111/cas.14967 · Cited by 41
Reschke, R., Gussek, P., Boldt, A., Sack, U., Koehl, U., Lordick, F., Gora, T., Kreuz, M., Reiche, K., Simon, J., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158017 · Cited by 45
“Food and Drug Administration (FDA) for adjuvant melanoma therapy [4].”
BackgroundSanaei, M., Pourbagheri‐Sigaroodi, A., Kaveh, V., Abolghasemi, H., Ghaffari, S. H., Momeny, M., & Bashash, D. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174404 · Cited by 36
Garrett, N. F. M. D. S., da Costa, A. C. C., Ferreira, E. B., Damiani, G. B., dos Reis, P. E. D., & Vasques, C. I. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255716 · Cited by 38
“Most studies that presented grade 3 or 4 irAEs (n = 15) evaluated the use of ipilimumab alone [27,29,31,43,47,48,51–53] or in combination therapy [30,38,41,56,63,64].”
BackgroundMethodInfluentialAdjuvant treatment for melanoma in clinical practice – Trial versus reality
de Meza, M. M., Ismail, R. K., Rauwerdink, D. J. W., van Not, O. J., van Breeschoten, J., Blokx, W. A. M., de Boer, A., van Dartel, M., Hilarius, D. L., Ellebæk, E., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.044 · Cited by 36
Nuclear PD-L1 promotes cell cycle progression of BRAF-mutated colorectal cancer by inhibiting THRAP3
Ma, R., Liu, Y., Che, X., Li, C., Wen, T., Hou, K., & Qu, X. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.12.017 · Cited by 38
Akai, M., Noma, K., Kato, T., Nishimura, S., Matsumoto, H., Kawasaki, K., Kunitomo, T., Kobayashi, T., Nishiwaki, N., Kashima, H., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02639-1 · Cited by 39
“Consequently, immune checkpoint inhibitors (ICIs) such as anti-PD-1 and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) antibody therapies have become integral components of clinical practice [3, 8 – 10].”
BackgroundMotzer, R. J., Bex, A., Russo, P., Tomita, Y., Cutuli, H. J., Rojas, C. A., Gross‐Goupil, M., Schinzari, G., Melichar, B., Barthélémy, P., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00773 · Cited by 48
The adjuvant treatment revolution for high-risk melanoma patients
Spagnolo, F., Boutros, A., Tanda, E. T., & Queirolo, P. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.024 · Cited by 38
Self-citationRuggiero, R., Fraenza, F., Scavone, C., di Mauro, G., Piscitelli, R., Mascolo, A., Ferrajolo, C., Rafaniello, C., Sportiello, L., Rossi, F., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00830 · Cited by 38
MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans
Esposito, I., Cicconi, P., D’Alise, A. M., Brown, A., Esposito, M., Swadling, L., Holst, P. J., Bassi, M. R., Stornaiuolo, M., Mori, F., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz7715 · Cited by 39
Metadata
- Authors
- Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J.-J., Butler, M. O., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., Gonzalez, R., Kudchadkar, R. R., Smylie, M., Meyer, N., Mortier, L., Atkins, M. B., Long, G. V., Bhatia, S., Lebbé, C., Rutkowski, P., Yokota, K., Yamazaki, N., Kim, T. M., de Pril, V., Sabater, J., Qureshi, A., Larkin, J., & Ascierto, P. A.
- Affiliations
- University of Siena (IT)
- ORCID
- Weber, Jeffrey
- Gogas, Helen J.
- Arance, Ana M.
- Cowey, C. Lance
- Dalle, Stéphane
- Schenker, Michael
- Grob, Jean-Jacques
- Butler, Marcus O.
- Middleton, Mark R.
- Maio, Michele
- Atkinson, Victoria
- Queirolo, Paola
- Gonzalez, Rene
- Kudchadkar, Ragini R.
- Smylie, Michael
- Mortier, Laurent
- Atkins, Michael B.
- Long, Georgina V.
- Bhatia, Shailender
- Rutkowski, Piotr
- Yokota, Kenji
- Yamazaki, Naoya
- Sabater, Javier
- Larkin, James
- Ascierto, Paolo A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-09
- Volume
- 377
- Issue
- 19
- Pages
- 1824-1835
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2752227448
- Cited by
- 2,246
- References
- 19
- Citations by year
- 2026: 105 · 2025: 155 · 2024: 218 · 2023: 228 · 2022: 265 · 2021: 339 · 2020: 347 · 2019: 315 · 2018: 245 · 2017: 24
- FWCI
- 112.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
- Research Explorer (The University of Manchester) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Cancer Research UK (18892, 15951, 20613, 22795)
- Medical Research Council (MR/P024351/1)
- Japan Society for the Promotion of Science (16K10165)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- nivolumab, ipilimumab, adjuvant therapy, advanced melanoma, immune checkpoint inhibitors, recurrence-free survival, PD-1 inhibitors, CTLA-4 inhibitors, R0 resection, treatment-related adverse events, melanoma recurrence, overall survival, progression-free survival
- MeSH terms
- Ipilimumab, Nivolumab, Cutaneous Malignant Melanoma, Adjuvants, Immunologic, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Quality of Life, Skin Neoplasms, Disease-Free Survival, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.